Spectral Diagnostics (OTCMKTS:EDTXF) Trading Down 1.5% – What’s Next?

Spectral Diagnostics Inc. (OTCMKTS:EDTXF)’s stock price dropped 1.5% on Friday . The company traded as low as $0.9026 and last traded at $0.9378. Approximately 119,246 shares were traded during mid-day trading, an increase of 1,464% from the average daily volume of 7,627 shares. The stock had previously closed at $0.9520.

Spectral Diagnostics Price Performance

The business’s fifty day moving average is $1.00 and its 200-day moving average is $0.87. The firm has a market cap of $271.17 million, a PE ratio of -8.53 and a beta of 0.09.

Spectral Diagnostics (OTCMKTS:EDTXF) last released its earnings results on Friday, November 7th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). The business had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.